Trial Profile
A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Autologous mesenchymal stem cell therapy Pharmicell (Primary)
- Indications Adult respiratory distress syndrome
- Focus Therapeutic Use
- Acronyms STELLAR
- 17 Feb 2016 New trial record